MDNA:CA:TSX-Medicenna Therapeutics Corp (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 5.13

Change

-0.07 (-1.35)%

Market Cap

CAD 0.28B

Volume

0.18M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AUP:CA Aurinia Pharmaceuticals Inc

+0.23 (+1.27%)

CAD2.30B N/A N/A
TRIL:CA Trillium Therapeutics Inc

-0.97 (-6.30%)

CAD1.55B 1.80 N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
APS:CA Aptose Biosciences Inc

-0.14 (-2.69%)

CAD0.46B N/A N/A
BLU:CA BELLUS Health Inc

+0.01 (+0.20%)

CAD0.39B N/A N/A
IMV:CA IMV Inc

-0.20 (-4.49%)

CAD0.30B -99,999.99 N/A
FRX:CA Fennec Pharmaceuticals Inc

-0.61 (-5.94%)

CAD0.27B 30.20 N/A
RVX:CA Resverlogix Corp

-0.04 (-3.92%)

CAD0.24B 56.67 27.58
ATE:CA Antibe Therapeutics Inc

-0.41 (-7.55%)

CAD0.21B N/A N/A
ONC:CA Oncolytics Biotech Inc

-0.49 (-10.10%)

CAD0.21B N/A N/A

ETFs Containing MDNA:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.78% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.78% 12% F 5% F
Trailing 12 Months  
Capital Gain 53.59% 76% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.59% 76% C 92% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 74.28% 76% C 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.28% 76% C 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 162.99% 18% F 2% F
Risk Adjusted Return 45.57% 53% F 61% D-
Market Capitalization 0.28B 67% D+ 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.40 63% D 86% B
Price/Book Ratio 8.10 44% F 13% F
Price / Cash Flow Ratio -30.72 89% B+ 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -71.85% 71% C- 10% F
Return on Invested Capital -42.54% 78% C+ 7% F
Return on Assets -41.10% 67% D+ 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.26 44% F 45% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.71 56% F 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector